drugset / Trial / NCT02722733

Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

NCT02722733 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in Hodgkin's lymphoma and non-Hodgkin's lymphoma patients.

Timeline

Start
2016-03
Primary completion
2017-03
Completion
2017-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cytarabine Small molecule 0.4 g/kg Intravenous
Comparator filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Comparator filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous